Description of the torcetrapib series of cholesteryl ester transfer protein inhibitors, including mechanism of action
about
Evacetrapib is a novel, potent, and selective inhibitor of cholesteryl ester transfer protein that elevates HDL cholesterol without inducing aldosterone or increasing blood pressureCrystal Structures of Cholesteryl Ester Transfer Protein in Complex with InhibitorsNew Era of Lipid-Lowering DrugsJTT-705: is there still future for a CETP inhibitor after torcetrapib?Anacetrapib, a Novel CETP Inhibitor: Pursuing a New Approach to Cardiovascular Risk ReductionDalcetrapib: no off-target toxicity on blood pressure or on genes related to the renin-angiotensin-aldosterone system in ratsCholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors.Surface plasmon resonance analysis of the mechanism of binding of apoA-I to high density lipoprotein particles.Cholesteryl ester transfer protein inhibition as a strategy to reduce cardiovascular risk.A vaccine targeted at CETP alleviates high fat and high cholesterol diet-induced atherosclerosis and non-alcoholic steatohepatitis in rabbit.Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial.The inhibition of cholesteryl ester transfer protein: a long and winding roadCETP inhibitors downregulate hepatic LDL receptor and PCSK9 expression in vitro and in vivo through a SREBP2 dependent mechanism.Patient considerations and clinical impact of cholesteryl ester transfer protein inhibitors in the management of dyslipidemia: focus on anacetrapib.CETP inhibition in cardiovascular risk management: a critical appraisal.Targeting high-density lipoprotein cholesterol in the management of cardiovascular disease.Future of cholesteryl ester transfer protein (CETP) inhibitors: a pharmacological perspective.Viability of developing CETP inhibitors.Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes.Anacetrapib and dalcetrapib: two novel cholesteryl ester transfer protein inhibitors.Emerging drugs for coronary artery disease. From past achievements and current needs to clinical promises.Structural and biophysical insight into cholesteryl ester-transfer protein.Investigational CETP antagonists for hyperlipidemia and atherosclerosis prevention.Cholesteryl ester transfer-protein modulator and inhibitors and their potential for the treatment of cardiovascular diseases.High-density lipoproteins in the prevention of cardiovascular disease: changing the paradigm.Identification of a novel, non-tetrahydroquinoline variant of the cholesteryl ester transfer protein (CETP) inhibitor torcetrapib, with improved aqueous solubility.Multidimensional profiling of plasma lipoproteins by size exclusion chromatography followed by reverse-phase protein arrays.Assessment of cholesteryl ester transfer protein inhibitors for interaction with proteins involved in the immune response to infection.Inhibition of CETP activity by torcetrapib reduces susceptibility to diet-induced atherosclerosis in New Zealand White rabbits.Biochemical characterization of cholesteryl ester transfer protein inhibitorsModulating cholesteryl ester transfer protein activity maintains efficient pre-β-HDL formation and increases reverse cholesterol transport.Molecular mechanism of apolipoprotein E binding to lipoprotein particles.HDL remodelingMultiple-dose pharmacodynamics and pharmacokinetics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects.Quantitative In Vitro Assessment of Liposome Stability and Drug Transfer Employing Asymmetrical Flow Field-Flow Fractionation (AF4).The withdrawal of torcetrapib from drug development: implications for the future of drugs that alter HDL metabolism.Binding profiles of cholesterol ester transfer protein with current inhibitors: a look at mechanism and drawback.Effect of crocin, a carotenoid from saffron, on plasma cholesteryl ester transfer protein and lipid profile in subjects with metabolic syndrome: A double blind randomized clinical trial.CETP + spherical HDL + torcetrapib => CETP:spherical HDL:torcetrapib complex
P2860
Q24624286-6B5B3F5D-B27A-4F04-B62A-590F387A4486Q27672820-5B78DA63-7974-4A58-A0A6-79D1351B7A7DQ28072298-BF66D563-AC3C-49BD-A687-43A6F8411A51Q28294797-8C19091D-5F00-41A7-BF9F-3D203208B0C3Q29999973-8575376F-4F8B-47EF-9FAF-F05D119929CCQ33569541-683454BA-D7DC-4E7B-B020-20623C1EBC3DQ33590777-A8A51EBF-3C94-4556-9584-0AFE48C1D3F0Q33634176-356DE7A1-3A36-43A0-8244-38390E91A700Q34253290-ADFF91B8-3B85-4C0C-8692-453300C74000Q34653513-D94ECBB9-8C83-4A58-AF2F-9A3E2A4D80D6Q35937805-487EF6D9-9EE2-46F1-ABDA-DBCD8B27A71EQ35958413-94CFBA5B-4E3B-40F9-94A5-4BD48A708E20Q35963040-78B259C0-52D7-4686-911D-3F940E69418CQ36197709-348D72AE-AC05-4191-989A-3689161E88C1Q36705260-F51CACE3-B82B-493D-9052-795F1CD62667Q36992708-B8545630-5F10-421F-90D6-E95D402AF671Q37038670-56D5809D-49AE-4B8F-9F4C-F0170CD20DD9Q37165682-588D6125-F1DE-4139-9A47-76C0FBFE94ADQ37254899-1302A905-63BC-417E-B369-FB750FFC1790Q37826018-250DAC33-02A1-49FD-BAAD-2B4D2575F489Q37827882-3BBC9DA5-2323-4124-9D33-07889AF9FEF8Q37905146-9B86ADC0-7009-4F52-AB75-715F5F004B89Q37941053-A342644D-44E7-4AA6-8583-8981A7920F5CQ38015817-370CF6C3-9BE8-4BB7-B6B9-5823323EADA4Q38203096-B43F38F7-D3D8-43C0-8C1A-3BF37B4A3417Q38418951-F8B69202-3EE4-430C-AF13-25E30856613DQ39234722-8F0CA2FF-904C-4210-9F71-2CE63FE89F91Q39994010-C91830DE-3E53-451E-A500-05903EFBDA06Q40166036-8F74E9FA-03CE-4413-B124-600E473EB153Q42107210-379D8E08-A5EA-4F3A-979A-0A8C13B293E1Q42126715-1CB024F5-20AC-4FBB-9C78-6F758F0BDBC8Q42589582-6A96E2E9-4BDA-40E7-8AC9-9E27E0D0F189Q45318424-78901195-2ADC-4DFF-8FC8-3BD3CF01A9F1Q46518415-9E6CFF90-8CB9-4CEE-AB08-F1A030F8B237Q46635086-C8A67208-23C0-4E24-B563-0D5CDCA7CD14Q46961293-FA6528DF-2A8F-4905-B232-5136C68DD878Q47990605-D1DBADCC-111E-4F04-B437-4C5B7731B9B4Q49279420-CDC0F59D-56ED-432C-87C0-9FD7D991EC06Q50299773-0C9ED0B2-285A-45B9-94BA-C84392C0D35E
P2860
Description of the torcetrapib series of cholesteryl ester transfer protein inhibitors, including mechanism of action
description
2006 nî lūn-bûn
@nan
2006 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի մարտին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Description of the torcetrapib ...... including mechanism of action
@ast
Description of the torcetrapib ...... including mechanism of action
@en
Description of the torcetrapib ...... including mechanism of action
@nl
type
label
Description of the torcetrapib ...... including mechanism of action
@ast
Description of the torcetrapib ...... including mechanism of action
@en
Description of the torcetrapib ...... including mechanism of action
@nl
prefLabel
Description of the torcetrapib ...... including mechanism of action
@ast
Description of the torcetrapib ...... including mechanism of action
@en
Description of the torcetrapib ...... including mechanism of action
@nl
P2093
P2860
P1476
Description of the torcetrapib ...... including mechanism of action
@en
P2093
David Cunningham
Mark J Bamberger
Roger B Ruggeri
Ronald W Clark
P2860
P304
P356
10.1194/JLR.M500349-JLR200
P407
P577
2006-03-01T00:00:00Z